undamentalytics Newsletter
Sign in

Cue Biopharma, Inc. balance sheet

At the end of fiscal 2025, Cue Biopharma, Inc. had total assets of $42.2m, total liabilities of $15.8m and shareholders' equity of $26.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents214475645249222717
Receivables—11302165
Total current assets416188687751253727
Total assets4572100839162324231
Accounts payable212334344
Total current liabilities61216131217141321
Short-term debt————240——
Long-term debt———0840——
Total debt00001084—0
Total liabilities111721182624151628
Shareholders' equity34557965663717262
Shares outstanding21m27m30m32m—47m62m97m5m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CUE vs ZYMECUE vs NBTXCUE vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cue Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cue Biopharma, Inc.